Drugs / TDF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03662568 | Jun → Jul 2018 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03662568 ↗ |
| Route | Oral | “Administered TDF 300 mg orally once daily in fasted state” NCT03662568 ↗ |